Does Strattera Cause Drowsiness?
Strattera (atomoxetine) can cause somnolence (drowsiness) as a common adverse effect, though it is generally less likely to disrupt sleep compared to stimulant medications used for ADHD. In fact, atomoxetine may be preferred when sleep disturbances are already present, as it appears more "sleep neutral" than alternatives like methylphenidate.
Understanding the Drowsiness Profile
According to FDA labeling data, somnolence is listed among the most common adverse effects of atomoxetine in pediatric clinical trials, occurring frequently enough to warrant mention alongside nausea, vomiting, fatigue, decreased appetite, and abdominal pain 1. The drug label specifically notes that somnolence was a reason for discontinuation in 0.3% of pediatric patients in clinical trials 1.
However, the context matters significantly:
Atomoxetine causes less sleep disruption than stimulants like methylphenidate. In a head-to-head comparison, atomoxetine resulted in significantly shorter sleep-onset latency (12.1 minutes) compared to methylphenidate (39.2 minutes increase from baseline) 2.
The drowsiness effect can be strategically managed through dosing timing. Guidelines note that atomoxetine can be split into two doses (morning and evening) or, if needed, administered in the evening only to reduce adverse effects 3.
Clinical Context and Comparative Safety
Within the non-stimulant class, atomoxetine's adverse effects are considered less frequent and less pronounced compared to clonidine and guanfacine 3, which commonly cause somnolence, fatigue, and sedation as their most frequent side effects 3.
The evidence suggests atomoxetine occupies a middle ground:
- More likely to cause drowsiness than stimulants causing insomnia
- Less likely to cause problematic sedation than alpha-2 agonists (clonidine/guanfacine)
- Generally well-tolerated with most adverse events being mild to moderate 4
Practical Management Approach
If drowsiness occurs with atomoxetine:
- Consider evening-only dosing rather than morning administration, as this is explicitly supported in guidelines 3
- Monitor for the first 6-12 weeks, as therapeutic effects take time to develop and side effects may diminish 3
- Assess whether the patient is a CYP2D6 poor metabolizer (approximately 7% of Caucasian populations), as these individuals have 10-fold higher drug exposure and experience more adverse effects including drowsiness 3, 1
Important Caveats
- The drowsiness is typically not severe enough to cause discontinuation in most patients (only 0.3% discontinued for this reason) 1
- Atomoxetine may actually improve sleep quality overall in children with ADHD compared to stimulants, with parents reporting children had less difficulty falling asleep and slept better 2
- In patients with autism spectrum disorder and ADHD, atomoxetine appears "sleep neutral" and may be preferred over psychostimulants when sleep disturbance is already an issue 5
The bottom line: Yes, Strattera can make you drowsy, but this side effect is manageable through dose timing adjustments and is generally less problematic than the insomnia caused by stimulant alternatives.